Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Precision Flora is a microbiome-focused biotechnology company that develops precision-engineered prebiotics designed to modulate the human gut microbiome with high specificity. Moving beyond generic fiber supplements, the company utilizes a proprietary scientific platform to identify specific complex carbohydrates that selectively nourish beneficial bacterial taxa, such as Bifidobacteria and butyrate-producing species. Founded by prominent gastroenterologist Dr. Will Bulsiewicz and a team of microbiome experts, Precision Flora integrates clinical research with advanced microbiome mapping to address conditions linked to gut dysbiosis, including digestive disorders and metabolic imbalances. Their approach aims to provide targeted nutritional interventions that optimize the gut-immune and gut-brain axes. The company's flagship products are currently available in the consumer health market, while they continue to expand their research into targeted microbiome modulators for broader therapeutic applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Precision Flora.